Economic impact of primary open-angle glaucoma in Australia

Clinical and Experimental Ophthalmology

Volumn 39, Issue 7, 2011, Pages 623-632

  Dirani, Mohamed ^a   Crowston, Jonathan G ^b   Taylor, Penny S ^c   Moore, Peter T ^c   Rogers, Sophie ^c   Pezzullo, M Lynne ^c   Keeffe, Jill E ^a   Taylor, Hugh R ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b ROYAL VICTORIAN EYE AND EAR HOSPITAL   (Australia)

^c Access Economics Pty Limited   (Australia)

Author keywords

Economics; Glaucoma; Quality of life

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT;

AGING; ARTICLE; AUSTRALIA; BLINDNESS; COMORBIDITY; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; DEPRESSION; DISEASE COURSE; DISEASE SEVERITY; ELDERLY CARE; FALL RISK; FALLING; HEALTH CARE COST; HEALTH ECONOMICS; HIP FRACTURE; HOSPITAL COST; HUMAN; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; LOW LEVEL LASER THERAPY; MORTALITY; NURSING HOME; OPEN ANGLE GLAUCOMA; OUTCOME ASSESSMENT; QUALITY OF LIFE; RISK FACTOR; TRABECULECTOMY; TRABECULOPLASTY; TREATMENT RESPONSE; UNEMPLOYMENT; VISUAL ACUITY; VISUAL FIELD; VISUAL IMPAIRMENT; WELLBEING;

ACCIDENTAL FALLS; ADULT; AGED; AGED, 80 AND OVER; ANTIHYPERTENSIVE AGENTS; AUSTRALIA; COST-BENEFIT ANALYSIS; DEPRESSIVE DISORDER; DIAGNOSTIC TECHNIQUES, OPHTHALMOLOGICAL; FEMALE; GLAUCOMA, OPEN-ANGLE; HEALTH CARE COSTS; HUMANS; LASER THERAPY; MALE; MIDDLE AGED; PREVALENCE; QUALITY OF LIFE; QUALITY-ADJUSTED LIFE YEARS; RISK FACTORS; TRABECULECTOMY;

EID: 80053574076     PISSN: 14426404     EISSN: 14429071     Source Type: Journal    
DOI: 10.1111/j.1442-9071.2011.02530.x     Document Type: Article

References (47)

1. Resnikoff S, Pascolini D, Etya'ale D etal. Global data on visual impairment in the year 2002. Bull World Health Organ 2004; 82: 844-51.
2. Quigley HA, Broman AT. The number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmol 2006; 90: 262-7.
3. Broman AT, Quigley HA, West SK etal. Estimating the rate of progressive visual field damage in those with open-angle glaucoma, from cross-sectional data. Invest Ophthalmol Vis Sci 2008; 49: 66-76.
4. Wensor MD, McCarty CA, Stanislavsky YL etal. The prevalence of glaucoma in the Melbourne Visual Impairment Project. Ophthalmology 1998; 105: 733-9.
5. Friedman DS, Wolfs RC, O'Colmain BJ etal. Prevalence of open-angle glaucoma among adults in the United States. Arch Ophthalmol 2004; 122: 532-8.
6. Quigley HA, Vitale S. Models of open-angle glaucoma prevalence and incidence in the United States. Invest Ophthalmol Vis Sci 1997; 38: 83-91.
7. Weinreb RN, Khaw PT. Primary open-angle glaucoma. Lancet 2004; 363: 1711-20.
8. Kass MA, Heuer DK, Higginbotham EJ etal. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol 2002; 120: 701-13; discussion 829-30.
9. Heijl A, Leske MC, Bengtsson B etal. Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Arch Ophthalmol 2002; 120: 1268-79.
10. Taylor HR, Pezzullo ML, Keeffe JE. The economic impact and cost of visual impairment in Australia. Br J Ophthalmol 2006; 90: 272-5.
11. Weinreb RN, Friedman DS, Fechtner RD etal. Risk assessment in the management of patients with ocular hypertension. Am J Ophthalmol 2004; 138: 458-67.
12. Hattenhauer MG, Johnson DH, Ing HH etal. The probability of blindness from open-angle glaucoma. Ophthalmology 1998; 105: 2099-104.
13. Wilson MR. Progression of visual field loss in untreated glaucoma patients and suspects in St Lucia, West Indies. Trans Am Ophthalmol Soc 2002; 100: 365-410.
14. Wong EY, Keeffe JE, Rait JL etal. Detection of undiagnosed glaucoma by eye health professionals. Ophthalmology 2004; 111: 1508-14.
15. Kobelt G, Jonsson B, Bergstrom A etal. Cost-effectiveness analysis in glaucoma: what drives utility? Results from a pilot study in Sweden. Acta Ophthalmol Scand 2006; 84: 363-71.
16. Noe G, Ferraro J, Lamoureux E etal. Associations between glaucomatous visual field loss and participation in activities of daily living. Clin Experiment Ophthalmol 2003; 31: 482-6.
17. Mathers C, Vos T, Stevenson C. The Burden of Disease and Injury in Australia. AIHW cat. no. PHE 17. Canberra: AIHW, 1999.
18. Taylor HR, Keeffe JE, Mitchell PR, Pezzullo ML. Clear Insight: The Economic Impact of Vision Loss in Australia. Melbourne: Centre for Eye Research Australia, 2004.
19. Lachaine J, Hodge WG, Steffensen I etal. Prostaglandin analogues for ophthalmic use: a cost-effectiveness analysis. Can J Ophthalmol 2008; 43: 33-41.
20. Lamoureux EL, Chong E, Wang JJ etal. Visual impairment, causes of vision loss, and falls: the Singapore Malay eye study. Invest Ophthalmol Vis Sci 2008; 49: 528-33.
21. AGOS (Advanced Glaucoma Intervention Study) Investigators. The Advanced Glaucoma Intervention Study: 8. Risk of cataract formation after trabeculectomy. Arch Ophthalmol 2001; 119: 1771-9.
22. Glynn RJ, Seddon JM, Krug JH Jr etal. Falls in elderly patients with glaucoma. Arch Ophthalmol 1991; 109: 205-10.
23. Lee R, Hutnik CM. Projected cost comparison of selective laser trabeculoplasty versus glaucoma medication in the Ontario Health Insurance Plan. Can J Ophthalmol 2006; 41: 449-56.
24. Dolinis J, Harrison JE, Andrews GR. Factors associated with falling in older Adelaide residents. Aust N Z J Public Health 1997; 21: 462-8.
25. Haymes SA, Leblanc RP, Nicolela MT etal. Risk of falls and motor vehicle collisions in glaucoma. Invest Ophthalmol Vis Sci 2007; 48: 1149-55.
26. Bramley T, Peeples P, Walt JG etal. Impact of vision loss on costs and outcomes in medicare beneficiaries with glaucoma. Arch Ophthalmol 2008; 126: 849-56.
27. Coleman AL, Stone K, Ewing SK etal. Higher risk of multiple falls among elderly women who lose visual acuity. Ophthalmology 2004; 111: 857-62.
28. Cummings SR, Nevitt MC, Browner WS etal. Risk factors for hip fracture in white women. Study of Osteoporotic Fractures Research Group. N Engl J Med 1995; 332: 767-73.
29. Black A, Wood J. Vision and falls. Clin Exp Optom 2005; 88: 212-22.
30. Arfken CL, Lach HW, Birge SJ, Miller JP. The prevalence and correlates of fear of falling in elderly persons living in the community. Am J Public Health 1994; 84: 565-70.
31. Ivers RQ, Cumming RG, Mitchell P, Attebo K. Visual impairment and falls in older adults: the Blue Mountains Eye Study. J Am Geriatr Soc 1998; 46: 58-64.
32. Ramrattan RS, Wolfs RC, Panda-Jonas S etal. Prevalence and causes of visual field loss in the elderly and associations with impairment in daily functioning: the Rotterdam Study. Arch Ophthalmol 2001; 119: 1788-94.
33. Tinetti ME, Speechley M, Ginter SF. Risk factors for falls among elderly persons living in the community. N Engl J Med 1988; 319: 1701-7.
34. Vu HT, Keeffe JE, McCarty CA, Taylor HR. Impact of unilateral and bilateral vision loss on quality of life. Br J Ophthalmol 2005; 89: 360-3.
35. Wang JJ, Mitchell P, Cumming RG, Smith W. Visual impairment and nursing home placement in olderAustralians: the Blue Mountains Eye Study. Ophthalmic Epidemiol 2003; 10: 3-13.
36. Wang JJ, Mitchell P, Smith W etal. Incidence of nursing home placement in a defined community. Med J Aust 2001; 174: 271-5.
37. Brody BL, Gamst AC, Williams RA etal. Depression, visual acuity, comorbidity, and disability associated with age-related macular degeneration. Ophthalmology 2001; 108: 1893-900; discussion 900-1.
38. Wilson MR, Coleman AL, Yu F etal. Depression in patients with glaucoma as measured by self-report surveys. Ophthalmology 2002; 109: 1018-22.
39. Canberra A. Productivity commission evaluation of the pharmaceutical industry investment program. Research Report. 2003.
40. Gordon MO, Kass MA. The Ocular Hypertension Treatment Study: design and baseline description of the participants. Arch Ophthalmol 1999; 117: 573-83.
41. Leske MC, Heijl A, Hyman L, Bengtsson B. Early Manifest Glaucoma Trial: design and baseline data. Ophthalmology 1999; 106: 2144-53.
42. Group TGLTR. The Glaucoma Laser Trial (GLT) and glaucoma laser trial follow-up study: 7. Results. Am J Ophthalmol 1995; 120: 718-31.
43. McIlraith I, Strasfeld M, Colev G, Hutnik CM. Selective laser trabeculoplasty as initial and adjunctive treatment for open-angle glaucoma. J Glaucoma 2006; 15: 124-30.
44. Leske MC, Heijl A, Hussein M etal. Factors for glaucoma progression and the effect of treatment: the early manifest glaucoma trial. Arch Ophthalmol 2003; 121: 48-56.
45. Fiscella RG, Green A, Patuszynski DH, Wilensky J. Medical therapy cost considerations for glaucoma. Am J Ophthalmol 2003; 136: 18-25.
46. Quigley HA. Number of people with glaucoma worldwide. Br J Ophthalmol 1996; 80: 389-93.
47. Mitchell P, Smith W, Attebo K, Healey PR. Prevalence of open-angle glaucoma in Australia. The Blue Mountains Eye Study. Ophthalmology 1996; 103: 1661-9.